On November 16th, the 2024 China Pharmaceutical Industry Development Conference and the Shanghai International Biomedical Industry Week were held in Shanghai on November 16th. According to the data released by the conference, since the "14th Five-Year Plan", the quantity and quality of domestic innovative drugs in our country have risen simultaneously, and a total of 113 domestic innovative drugs have been approved for listing, which is 2.8 times the number of new drugs approved in the "13th Five-Year Plan". The market size has reached 100 billion yuan. Since the "14th Five-Year Plan", our country's high-end medical apparatus has accelerated innovation and breakthroughs. A total of 165 innovative medical apparatus developed by Chinese enterprises have been approved for listing. The products are integrated with cutting-edge technologies such as deep learning, magnetic levitation, and additive manufacturing. " During the "14th Five-Year Plan" period, there are 130,000 pharmaceutical industry enterprises above designated size in our country, which can produce more than 20,000 kinds of medicines and medical apparatus.